Scienture Holdings, Inc. - SIC # 6794 - PATENT OWNERS AND LESSORS

Ticker Exchange SIC # Website Latest Ticker
SCNX Nasdaq 6794 scienture.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Scienture Holdings, Inc.

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance - Aug 14th, 2026 6:08 am
SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product - Aug 12th, 2026 8:13 am
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray - Aug 12th, 2026 6:05 am
EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US - Aug 12th, 2026 5:46 am
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers - Jul 9th, 2026 6:05 am
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide - Jun 18th, 2026 6:05 am
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team - Jun 9th, 2026 6:05 am
EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch - Jun 9th, 2026 5:46 am
SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC - Jun 4th, 2026 6:00 am
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041 - Jun 2nd, 2026 6:05 am
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion - May 18th, 2026 6:38 am
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline - May 7th, 2026 6:05 am
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041 - May 6th, 2026 6:05 am
Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Apr 15th, 2026 6:05 am
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead - Apr 6th, 2026 6:05 am
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update - Mar 30th, 2026 6:07 am
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions - Mar 11th, 2026 6:05 am